{"id":62135,"date":"2025-11-04T01:02:46","date_gmt":"2025-11-04T00:02:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/"},"modified":"2025-11-04T01:02:46","modified_gmt":"2025-11-04T00:02:46","slug":"tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/","title":{"rendered":"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes"},"content":{"rendered":"
\n

DALLAS–(BUSINESS WIRE)–Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.5 billion in aggregate principal amount of senior secured first lien notes due on November 15, 2032, which will bear interest at a rate of 5.500% per annum (the \u201cfirst lien notes\u201d), and $0.75 billion in aggregate principal amount of senior notes due November 15, 2033, which will bear interest at a rate of 6.000% per annum (the \u201csenior notes\u201d and together with the first lien notes, the \u201cnotes\u201d). The aggregate principal amount of senior notes to be issued in the offering was increased to $0.75 billion from the previously announced amount of $0.5 billion. Completion of the notes offering is expected to occur on November 18, 2025, and is subject to, among other things, customary closing conditions.<\/p>\n

<\/a>
<\/a><\/p>\n

\nTenet intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.5 billion outstanding of its 6.250% senior secured second lien notes due February 2027 (the \u201c2027 Notes\u201d) and the partial redemption of $0.75 billion outstanding of its 6.125% senior notes due October 2028 (the \u201c2028 Notes\u201d and together with the 2027 Notes, the \u201cRedemption Notes\u201d).<\/p>\n

\nThe first lien notes will be guaranteed by certain of Tenet\u2019s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of Tenet\u2019s subsidiaries. The first lien notes will be effectively senior to Tenet\u2019s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings. The senior notes will be Tenet\u2019s unsecured obligations and will rank equally in right of payment with its existing and future senior unsecured obligations, will rank senior in right of payment to all of Tenet\u2019s existing and future unsecured subordinated obligations, will be effectively subordinated to all of Tenet\u2019s existing and future senior secured obligations, including the first lien notes, to the extent of the value of the collateral securing Tenet\u2019s senior secured obligations and will be structurally subordinated to all obligations and liabilities of Tenet\u2019s subsidiaries to the extent of the value of the assets of such subsidiaries.<\/p>\n

\nThe notes to be offered will not be registered under the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), or any other state securities laws. As a result, they may not be offered or sold in the United States or to any U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the notes will be offered only to persons reasonably believed to be \u201cqualified institutional buyers\u201d under Rule 144A of the Securities Act or, outside the United States, to persons other than \u201cU.S. persons\u201d in compliance with Regulation S under the Securities Act. A confidential offering memorandum for the notes will be made available to such eligible persons. The offerings will be conducted in accordance with the terms and subject to the conditions set forth in such offering memorandum.<\/p>\n

\nThis news release is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This news release shall not constitute a notice of redemption of the Redemption Notes.<\/p>\n

\nCautionary Statement<\/b><\/p>\n

\nThis release contains \u201cforward-looking statements\u201d – that is, statements that relate to future, not past, events. In this context, forward-looking statements often address Tenet\u2019s expected future business and financial performance and financial condition, and often contain words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201cbudget,\u201d \u201cestimate,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201csee,\u201d \u201ctarget,\u201d or \u201cwill.\u201d Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause Tenet\u2019s actual results to be materially different than those expressed in Tenet\u2019s forward-looking statements include, but are not limited to the factors disclosed under \u201cForward-Looking Statements\u201d and \u201cRisk Factors\u201d in our Form 10-K for the year ended December 31, 2024, subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission.<\/p>\n

\nAbout Tenet Healthcare<\/b><\/p>\n

\nTenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Will McDowell
\n
469-893-2387
\n
william.mcdowell@tenethealth.com<\/a><\/p>\n

\nMedia Contact:<\/b>
Robert Dyer
\n
469-893-2640
\n
mediarelations@tenethealth.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DALLAS–(BUSINESS WIRE)–Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.5 billion in aggregate principal amount of senior secured first lien notes due on November 15, 2032, which will bear interest at a rate of 5.500% per annum (the \u201cfirst lien … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62135","6":"format-standard","7":"category-industry"},"yoast_head":"\nTenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DALLAS–(BUSINESS WIRE)–Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.5 billion in aggregate principal amount of senior secured first lien notes due on November 15, 2032, which will bear interest at a rate of 5.500% per annum (the \u201cfirst lien ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T00:02:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251103122310\/en\/754022\/22\/TenetHealth_rounded.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes\",\"datePublished\":\"2025-11-04T00:02:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/\"},\"wordCount\":859,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251103122310\\\/en\\\/754022\\\/22\\\/TenetHealth_rounded.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/\",\"name\":\"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251103122310\\\/en\\\/754022\\\/22\\\/TenetHealth_rounded.jpg\",\"datePublished\":\"2025-11-04T00:02:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251103122310\\\/en\\\/754022\\\/22\\\/TenetHealth_rounded.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251103122310\\\/en\\\/754022\\\/22\\\/TenetHealth_rounded.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/","og_locale":"en_US","og_type":"article","og_title":"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes - Pharma Trend","og_description":"DALLAS–(BUSINESS WIRE)–Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.5 billion in aggregate principal amount of senior secured first lien notes due on November 15, 2032, which will bear interest at a rate of 5.500% per annum (the \u201cfirst lien ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-04T00:02:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251103122310\/en\/754022\/22\/TenetHealth_rounded.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes","datePublished":"2025-11-04T00:02:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/"},"wordCount":859,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251103122310\/en\/754022\/22\/TenetHealth_rounded.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/","url":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/","name":"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251103122310\/en\/754022\/22\/TenetHealth_rounded.jpg","datePublished":"2025-11-04T00:02:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251103122310\/en\/754022\/22\/TenetHealth_rounded.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251103122310\/en\/754022\/22\/TenetHealth_rounded.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tenet-announces-upsizing-and-pricing-of-its-2-25-billion-private-offerings-of-senior-secured-notes-and-senior-notes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62135"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62135\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}